Basic Stats
| LEI | 529900NMN0LACZOL7C43 |
| CIK | 1453687 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Cartesian Therapeutics, Inc.
SEC Filings (Chronological Order)
This page provides a complete, chronological list of SEC Filings, excluding ownership filings which we provide elsewhere.
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 CARTESIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37798 26-1622110 (State or other jurisdiction of incorporation) (Commis |
|
| August 7, 2025 |
Amendment to Lease Agreement by and between 7495 RP, LLC and Cartesian Therapeutics, Inc. dated Exhibit 10.1 FOURTH AMENDMENT TO LEASE AGREEMENT THIS FOURTH AMENDMENT TO LEASE AGREEMENT (this “Fourth Amendment”) is made and entered into this 26th day of June, 2025 (“Effective Date”), by and between 7495 RP, LLC, a Maryland limited liability company, having an address at 5377 Jackson Mountain Road, Frederick, Maryland 21702 (“Landlord”), and CARTESIAN THERAPEUTICS, INC., a Delaware corporatio |
|
| August 7, 2025 |
Exhibit 99.1 Cartesian Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update Initiated Phase 3 AURORA trial of Descartes-08 in myasthenia gravis Preliminary data from Phase 2 trial of Descartes-08 in systemic lupus erythematosus expected in 2H25 Initiation of Phase 2 pediatric basket trial of Descartes-08 in select autoimmune indications expected in 2H25 Approxima |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37798 Cartesian Therapeutic |
|
| June 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2025 CARTESIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37798 26-1622110 (State or other jurisdiction of incorporation) (Commiss |
|
| May 30, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2025 CARTESIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37798 26-1622110 (State or other jurisdiction of incorporation) (Commissi |
|
| May 30, 2025 |
Exhibit 99.1 Cartesian Therapeutics Announces First Participant Enrolled in the Phase 3 AURORA Trial of Descartes-08 in Patients with Myasthenia Gravis FREDERICK, MD, May 30, 2025 (GLOBE NEWSWIRE) – Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (“Cartesian” or the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that the first partic |
|
| May 8, 2025 |
Exhibit 99.1 Cartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update Initiation of Phase 3 AURORA trial of Descartes-08 in myasthenia gravis expected in 2Q25; deep and sustained benefits observed through Month 12 after a single course of therapy in Phase 2b trial Preliminary data from Phase 2 trial of Descartes-08 in systemic lupus erythematosus expected in |
|
| May 8, 2025 |
As filed with the Securities and Exchange Commission on May 8, 2025 As filed with the Securities and Exchange Commission on May 8, 2025 Registration No. |
|
| May 8, 2025 |
Exhibit 10.1 THIRD AMENDMENT TO LEASE AGREEMENT THIS THIRD AMENDMENT TO LEASE AGREEMENT (this “Third Amendment”) is made and entered into this 13th day of March, 2025 (“Effective Date”), by and between 7495 RP, LLC, a Maryland limited liability company, having an address at 5377 Jackson Mountain Road, Frederick, Maryland 21702 (“Landlord”), and CARTESIAN THERAPEUTICS, INC., a Delaware corporation, |
|
| May 8, 2025 |
Exhibit 10.2 Separation Agreement and Release This Separation Agreement and Release (“Agreement”) is made by and between Metin Kurtoglu (“Executive”) and Cartesian Therapeutics, Inc. (the “Company”) (collectively referred to as the “Parties” or individually referred to as a “Party”). Capitalized terms used but not defined in this Agreement shall have the meanings set forth in the Employment Agreem |
|
| May 8, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025 CARTESIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37798 26-1622110 (State or other jurisdiction of incorporation) (Commissio |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37798 Cartesian Therapeuti |
|
| May 8, 2025 |
Exhibit 107.1 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) Cartesian Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1 - Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount to be Registered (1) Proposed Maximum Offering Price Per Share Proposed Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2025 CARTESIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37798 26-1622110 (State or other jurisdiction of incorporation) (Commis |
|
| April 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant þ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| April 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 8, 2025 CARTESIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37798 26-1622110 (State or other jurisdiction of incorporation) (Commiss |
|
| April 8, 2025 |
Pioneering mRNA Cell Therapy for Autoimmunity April 2025 Exhibit 99.2 Disclosures For the purposes of this notice, the “presentation” that follows shall mean and include the slides that follow, the oral presentation of the slides by members of management of Cartesian Therapeutics, Inc. (the “Company”) or any person on their behalf, any question-and-answer session that follows such oral presentatio |
|
| April 8, 2025 |
Exhibit 99.1 Cartesian Therapeutics’ Descartes-08 Observed to Provide Deep and Sustained Benefits Through Month 12 After a Single Course of Therapy in Phase 2b Myasthenia Gravis Trial After a single course of therapy, Descartes-08-treated participants were observed to sustain deep responses through long-term follow-up, with an average 4.8-point reduction in MG-ADL at Month 12 Deepest and most comp |
|
| March 13, 2025 |
Exhibit 10.3 CARTESIAN THERAPEUTICS, INC. AMENDED AND RESTATED 2018 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN ARTICLE I. PURPOSE The Plan’s purpose is to enhance the Company’s ability to attract, retain and motivate persons who are expected to make important contributions to the Company by providing these individuals with equity ownership opportunities. Capitalized terms used in the Plan are defi |
|
| March 13, 2025 |
Non-Employee Director Compensation Program Exhibit 10.5 CARTESIAN THERAPEUTICS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM Non-employee members of the board of directors (the “Board”) of Cartesian Therapeutics, Inc. (the “Company”) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this “Program”), as amended by the Board effective December 12,2024 (the “Effective Date”). The ca |
|
| March 13, 2025 |
Exhibit 4.12 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED As of December 31, 2024, Cartesian Therapeutics, Inc. (the “Company,” “we,” “us” and “our”) had two classes of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock, par value $0.0001 per share (“common st |
|
| March 13, 2025 |
Specimen Stock Certificate evidencing the shares of common stock NUMBER SHARES COUNTERSIGNED: BROADRIDGE CORPORATE ISSUER SOLUTIONS, LLC TRANSFER AGENT BY: AUTHORIZED SIGNATURE DATED: INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE CUSIP 816212 30 2 SEE REVERSE FOR CERTAIN DEFINITIONS This CerTifies ThaT: is The owner of C o M M o n s T o C K GENERAL COUNSEL AND SECRETARY PRESIDENT AND CHIEF EXECUTIVE OFFICER FULLY PAID AND NON-ASSESSABLE SHARES OF COMMON STOCK, $0. |
|
| March 13, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2025 CARTESIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37798 26-1622110 (State or other jurisdiction of incorporation) (Commis |
|
| March 13, 2025 |
Subsidiaries of Cartesian Therapeutics, Inc. Exhibit 21.1 Subsidiaries of Cartesian Therapeutics, Inc.: Name Jurisdiction of Organization Selecta (RUS) LLC Russia Cartesian Bio, LLC Delaware |
|
| March 13, 2025 |
Exhibit 99.1 Cartesian Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update Phase 3 AURORA trial of Descartes-08 in myasthenia gravis on track to commence in 1H25; Deep and durable responses maintained over 12 months in Descartes-08-treated participants in Phase 2b trial Phase 2 trial of Descartes-08 in systemic lupus erythematosus ongoing with expected data readout i |
|
| March 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37798 Cartesian Therapeutics, I |
|
| March 13, 2025 |
Cartesian Therapeutics, Inc. Insider Trading Policy Exhibit 19.1 CARTESIAN THERAPEUTICS, INC. INSIDER TRADING POLICY I. PURPOSE Cartesian Therapeutics, Inc. (“Cartesian” or the “Company”) has adopted the following policies and procedures with respect to trading in Cartesian securities by members of Company’s board of directors, officers and employees. These policies and procedures are designed to help you comply with insider trading laws, handle co |
|
| March 3, 2025 |
rnaccorporatedeckmarch25 Pioneering mRNA Cell Therapy for Autoimmunity March 2025 Exhibit 99. |
|
| March 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2025 CARTESIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37798 26-1622110 (State or other jurisdiction of incorporation) (Commiss |
|
| January 27, 2025 |
Exhibit 99.1 Cartesian Therapeutics Announces FDA Special Protocol Assessment Agreement for Phase 3 AURORA Trial of Descartes-08 in Myasthenia Gravis Trial on track to commence in 1H25 FREDERICK, Md., Jan. 27, 2025 (GLOBE NEWSWIRE) – Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announ |
|
| January 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 27, 2025 CARTESIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37798 26-1622110 (State or other jurisdiction of incorporation) (Comm |
|
| January 13, 2025 |
Exhibit 99.2 Cartesian Therapeutics Highlights Progress and 2025 Strategic Priorities Across Pipeline of mRNA Cell Therapies for Autoimmune Diseases Phase 3 AURORA trial of Descartes-08 in myasthenia gravis on track to commence in 1H25 Deepening responses observed over time in Descartes-08-treated participants in Phase 2b trial in myasthenia gravis; Safety profile continues to support outpatient a |
|
| January 13, 2025 |
Pioneering mRNA Cell Therapy for Autoimmunity January 2025 Exhibit 99.1 Disclosures For the purposes of this notice, the “presentation” that follows shall mean and include the slides that follow, the oral presentation of the slides by members of management of Cartesian Therapeutics, Inc. (the “Company”) or any person on their behalf, any question-and-answer session that follows such oral presentat |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 CARTESIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37798 26-1622110 (State or other jurisdiction of incorporation) (Comm |
|
| January 10, 2025 |
As filed with the Securities and Exchange Commission on January 10, 2025 As filed with the Securities and Exchange Commission on January 10, 2025 Registration No. |
|
| January 10, 2025 |
As filed with the Securities and Exchange Commission on January 10, 2025 As filed with the Securities and Exchange Commission on January 10, 2025 Registration No. |
|
| January 8, 2025 |
TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(7) Registration No. 333-283809 PROSPECTUS 11,392,350 Shares Cartesian Therapeutics, Inc. Common Stock Offered by the Selling Stockholders This prospectus relates to the proposed resale or other disposition by the selling stockholders identified herein, or the Selling Stockholders, of up to (i) 110,123 shares, or the Merger Common Shares, of our com |
|
| January 8, 2025 |
TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(7) Registration No. 333-283806 PROSPECTUS 6,251,150 Shares Cartesian Therapeutics, Inc. Common Stock Offered by the Selling Stockholders This prospectus relates to the proposed resale or other disposition by the selling stockholders identified herein, or the Selling Stockholders, of up to (i) 5,813,223 shares, or the Private Placement Common Shar |
|
| January 8, 2025 |
Up to $100,000,000 Common Stock TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(3) Registration No. 333-283803 PROSPECTUS Up to $100,000,000 Common Stock We have entered into a sales agreement, or the Sales Agreement, with Leerink Partners LLC, or Leerink Partners, dated December 13, 2024, relating to the sale of shares of our common stock, par value $0.0001 per share, or the Common Stock, offered by this prospectus. In acco |
|
| January 6, 2025 |
CORRESP 1 filename1.htm January 6, 2025 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attn: Doris Gama Re: Cartesian Therapeutics, Inc. Registration Statement on Form S-3 (the “Registration Statement”) File No. 333-283806 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Cartesian The |
|
| January 6, 2025 |
January 6, 2025 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attn: Doris Gama Re: Cartesian Therapeutics, Inc. Registration Statement on Form S-3 (the “Registration Statement”) File No. 333-283809 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Cartesian Therapeutics, Inc. (the “Co |
|
| January 6, 2025 |
January 6, 2025 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attn: Doris Gama Re: Cartesian Therapeutics, Inc. Registration Statement on Form S-3 (the “Registration Statement”) File No. 333-283803 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Cartesian Therapeutics, Inc. (the “Co |
|
| December 13, 2024 |
As filed with the Securities and Exchange Commission on December 13, 2024 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on December 13, 2024 Registration No. |
|
| December 13, 2024 |
As filed with the Securities and Exchange Commission on December 13, 2024 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on December 13, 2024 Registration No. |
|
| December 13, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Cartesian Therapeutics, Inc. |
|
| December 13, 2024 |
As filed with the Securities and Exchange Commission on December 13, 2024 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on December 13, 2024 Registration No. |
|
| December 13, 2024 |
Exhibit 1.2 Execution Version CARTESIAN THERAPEUTICS, INC. Shares of Common Stock ($0.0001 par value per share) SALES AGREEMENT December 13, 2024 LEERINK PARTNERS LLC 1301 Avenue of the Americas, 5th Floor New York, New York 10019 Ladies and Gentlemen: Cartesian Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Leerink Partners LLC (the “Age |
|
| December 13, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Cartesian Therapeutics, Inc. |
|
| December 13, 2024 |
CARTESIAN THERAPEUTICS, INC. Dated as of ___________, 20___ TABLE OF CONTENTS Exhibit 4.2 CARTESIAN THERAPEUTICS, INC. INDENTURE Dated as of , 20 [] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Other Definitions 4 Section 1.3. Incorporation by Reference of Trust Indenture Act 4 Section 1.4. Rules of Construction 5 ARTICLE II. THE SECURITIES 5 Section 2.1. Issuable in Series 5 Section 2.2. Esta |
|
| December 13, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Cartesian Therapeutics, Inc. |
|
| December 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 3, 2024 CARTESIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37798 26-1622110 (State or other jurisdiction of incorporation) (Comm |
|
| December 3, 2024 |
Exhibit 99.1 Cartesian Therapeutics Announces Positive Updated Results from Phase 2b Trial of Descartes-08 in Participants with Myasthenia Gravis and Outlines Design of Planned Phase 3 Trial Phase 3 AURORA trial on track to commence in 1H2025; Primary endpoint to assess proportion of Descartes-08-treated participants with myasthenia gravis demonstrating an MG-ADL improvement of ≥3 points at Month |
|
| December 3, 2024 |
Updated Data from Phase 2b Trial of Descartes-08 in Myasthenia Gravis December 3, 2024 Disclosures For the purposes of this notice, the “presentation” that follows shall mean and include the slides that follow, the oral presentation of the slides by members of management of Cartesian Therapeutics, Inc. |
|
| November 18, 2024 |
SC 13D/A 1 ea0221734-13da17springcart.htm AMENDMENT NO. 17 TO SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 17)* Cartesian Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 816212302 (CUSIP Number) Michael K. Bradshaw, Jr. Nelson Mu |
|
| November 7, 2024 |
Exhibit 107.1 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) Cartesian Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1 - Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount to be Registered (1) Proposed Maximum Offering Price Per Share Proposed Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity |
|
| November 7, 2024 |
Exhibit 99.1 Cartesian Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update Company expects to commence Phase 3 trial of Descartes-08 in patients with myasthenia gravis in 1H2025 following recent meeting with U.S. Food and Drug Administration Presentation of updated efficacy and safety data from Phase 2b trial and Phase 3 trial design of Descartes-08 in patients w |
|
| November 7, 2024 |
Exhibit 10.1 SECOND AMENDMENT TO LEASE AGREEMENT THIS SECOND AMENDMENT TO LEASE AGREEMENT (this “Second Amendment”) is made and entered into this 30th day of August, 2024 (“Effective Date”), by and between 7495 RP, LLC, a Maryland limited liability company, having an address at 5377 Jackson Mountain Road, Frederick, Maryland 21702 (“Landlord”), and CARTESIAN THERAPEUTICS, INC., a Delaware corporat |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37798 Cartesian Therap |
|
| November 7, 2024 |
As filed with the Securities and Exchange Commission on November 7, 2024 As filed with the Securities and Exchange Commission on November 7, 2024 Registration No. |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 CARTESIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37798 26-1622110 (State or other jurisdiction of incorporation) (Comm |
|
| October 15, 2024 |
RNAC / Cartesian Therapeutics, Inc. / Kalayoglu Murat - SC 13D/A Activist Investment SC 13D/A 1 d851731dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Cartesian Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 816212302 (CUSIP Number) William R. Kolb Daniel S. Clevenger Foley Hoag LLP 155 Seaport Boulevard Boston, |
|
| October 4, 2024 |
SC 13D/A 1 ea0216898-13da16springcart.htm AMENDMENT NO. 16 TO SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 16)* Cartesian Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 816212302 (CUSIP Number) Michael K. Bradshaw, Jr. Nelson Mu |
|
| October 1, 2024 |
TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(7) Registration No. 333-281204 PROSPECTUS 6,501,150 Shares Cartesian Therapeutics, Inc. Common Stock Offered by the Selling Stockholders This prospectus relates to the proposed resale or other disposition by the selling stockholders identified herein (the “Selling Stockholders”) of up to (i) 3,563,247 shares (the “Priv |
|
| September 27, 2024 |
September 27, 2024 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attn: Tyler Howes and Tim Buchmiller Re: Cartesian Therapeutics, Inc. Registration Statement on Form S-1 (the “Registration Statement”) File No. 333-281204 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Cartesian Ther |
|
| September 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 15)* Cartesian Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 816212302 (CUSIP Number) Michael K. Bradshaw, Jr. Nelson Mullins Riley & Scarborough LLP 101 Constitution Avenue NW, Suite 900 Washing |
|
| September 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 25, 2024 CARTESIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37798 26-1622110 (State or other jurisdiction of incorporation) (Co |
|
| September 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 20, 2024 CARTESIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37798 26-1622110 (State or other jurisdiction of incorporation) (Co |
|
| September 20, 2024 |
As filed with the Securities and Exchange Commission on September 20, 2024 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on September 20, 2024 Registration No. |
|
| September 20, 2024 |
September 20, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Tracie Mariner Kevin Vaughn Tyler Howes Tim Buchmiller Re: Cartesian Therapeutics, Inc. Amendment No. 1 to Registration Statement on Form S-1 Filed September 9, 2024 File No. 333-281204 Dear Ms. Mariner, Mr. Vaughn, Mr. Howes a |
|
| September 9, 2024 |
As filed with the Securities and Exchange Commission on September 9, 2024 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on September 9, 2024 Registration No. |
|
| September 9, 2024 |
Covington & Burling LLP One International Places Suite 1020 Boston, MA 02110-260 T +1 617 603 8800 September 9, 2024 VIA EDGAR U. |
|
| August 16, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Con |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 CARTESIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37798 26-1622110 (State or other jurisdiction of incorporation) (Commis |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37798 Cartesian Therapeutic |
|
| August 8, 2024 |
Exhibit 99.1 Cartesian Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update Presented positive topline results from Phase 2b trial of Descartes-08 in patients with myasthenia gravis; End-of-Phase 2 meeting with FDA expected by year-end Dosed first SLE patient in Phase 2 trial of Descartes-08 IND filing for pediatric basket study of Descartes-08 with focus in neur |
|
| August 8, 2024 |
® THERAPEUTICS Pioneering mRNA Cell Therapy for Autoimmunity August 2024 C A R T E S I A N T H E R A P E U T I C S Exhibit 99. |
|
| August 2, 2024 |
As filed with the Securities and Exchange Commission on August 2, 2024 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on August 2, 2024 Registration No. |
|
| August 2, 2024 |
Exhibit 10.3 CARTESIAN THERAPEUTICS, INC. AMENDED AND RESTATED 2018 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN ARTICLE I. Purpose The Plan’s purpose is to enhance the Company’s ability to attract, retain and motivate persons who are expected to make important contributions to the Company by providing these individuals with equity ownership opportunities. Capitalized terms used in the Plan are defi |
|
| August 2, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Conf |
|
| August 2, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Cartesian Therapeutics, Inc. |
|
| August 2, 2024 |
CARTESIAN THERAPEUTICS, INC. AMENDED AND RESTATED 2016 INCENTIVE AWARD PLAN Exhibit 10.1 CARTESIAN THERAPEUTICS, INC. AMENDED AND RESTATED 2016 INCENTIVE AWARD PLAN ARTICLE I. PURPOSE The Plan’s purpose is to enhance the Company’s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing these individuals with equity ownership opportunities. Capitalized terms used in the Plan are defined in Artic |
|
| August 2, 2024 |
CARTESIAN THERAPEUTICS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM Exhibit 10.6 CARTESIAN THERAPEUTICS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM Non-employee members of the board of directors (the “Board”) of Cartesian Therapeutics, Inc. (the “Company”) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this “Program”), as amended by the Board effective June 27, 2024 (the “Effective Date”). The cash |
|
| July 12, 2024 |
RNAC / Cartesian Therapeutics, Inc. / Artal International S.C.A. - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* (Amendment No. 2 ) Cartesian Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 816212104 (CUSIP Number) July 12, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to d |
|
| July 5, 2024 |
SC 13D/A 1 ea0208968-13da14springcart.htm AMENDMENT NO. 14 TO SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 14)* Cartesian Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 816212302 (CUSIP Number) Michael K. Bradshaw, Jr. Nelson Mu |
|
| July 2, 2024 |
Cartesian Therapeutics Announces $130 Million Private Placement Equity Financing Exhibit 99.1 Cartesian Therapeutics Announces $130 Million Private Placement Equity Financing GAITHERSBURG, MD, July 2, 2024 (GLOBE NEWSWIRE)—Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that it has entered into a securities purchase agreement for a private investment in pub |
|
| July 2, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of July 2, 2024, by and between Cartesian Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on Annex A hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). RECITALS A. The Company and each Purchaser is |
|
| July 2, 2024 |
Exhibit 3.1 CARTESIAN THERAPEUTICS, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES B NON-VOTING CONVERTIBLE PREFERRED STOCK Pursuant to Section 151 of the General Corporation Law of the State of Delaware THE UNDERSIGNED DOES HEREBY CERTIFY, on behalf of Cartesian Therapeutics, Inc., a Delaware corporation (the “Corporation”), that the following resolution was duly |
|
| July 2, 2024 |
Exhibit 99.3 Topline Data from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis July 2024 CARTESIAN THERAPEUTICS Disclosures and forward-looking statements Disclosures For the purposes of this notice, the “presentation” that follows shall mean and include the slides that follow, the oral presentation of the slides by members of management of Cartesian Therapeutics, Inc. (the “Comp |
|
| July 2, 2024 |
Exhibit 99.2 Cartesian Therapeutics Announces Positive Topline Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis Trial met primary endpoint with statistical significance, with 71% of myasthenia gravis patients treated with Descartes-08 observed to have a clinically meaningful improvement in MGC score at Month 3 compared to 25% for placebo Deep and durable responses up |
|
| July 2, 2024 |
Form of Registration Rights Agreement Exhibit 10.2 FORM OF REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is dated as of July 2, 2024, by and among Cartesian Therapeutics, Inc., a Delaware corporation (the “Company”), and the several purchasers signatory hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). This Agreement is made pursuant to the Secu |
|
| July 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2024 CARTESIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37798 26-1622110 (State or other jurisdiction of incorporation) (Commissi |
|
| June 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2024 CARTESIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37798 26-1622110 (State or other jurisdiction of incorporation) (Commiss |
|
| May 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2024 CARTESIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37798 26-1622110 (State or other jurisdiction of incorporation) (Commissi |
|
| May 22, 2024 |
Exhibit 99.1 Cartesian Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Descartes-08 for the Treatment of Myasthenia Gravis Topline data from Phase 2b trial of Descartes-08 in myasthenia gravis remains on track for mid-2024 GAITHERSBURG, MD, May 22, 2024 (GLOBE NEWSWIRE) – Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechno |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2024 CARTESIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37798 26-1622110 (State or other jurisdiction of incorporation) (Commissio |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37798 Cartesian Therapeuti |
|
| May 8, 2024 |
Exhibit 99.1 Cartesian Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update Topline data from Phase 2b trial of Descartes-08, the Company’s potential first-in-class mRNA CAR-T cell therapy, in myasthenia gravis on track for mid-2024 On track to dose first patient in Phase 2 trial of Descartes-08 in SLE in 2Q24, as well as Phase 2 basket studies in additional autoi |
|
| May 8, 2024 |
Exhibit 10.3(b) FIRST AMENDMENT TO LEASE AGREEMENT THIS FIRST AMENDMENT TO LEASE AGREEMENT (this “First Amendment”) is made and entered into this 7th day of May, 2024 (“Effective Date”), by and between 7495 RP, LLC, a Maryland limited liability company, having an address at 5377 Jackson Mountain Road, Frederick, Maryland 21702 (“Landlord”), and CARTESIAN THERAPEUTICS, INC., a Delaware corporation, |
|
| May 8, 2024 |
rnaccorporateslidedeckm ® THERAPEUTICS Pioneering mRNA Cell Therapy for Autoimmunity May 2024 C A R T E S I A N T H E R A P E U T I C S Exhibit 99. |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant þ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 19, 2024 CARTESIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37798 26-1622110 (State or other jurisdiction of incorporation) (Commis |
|
| April 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 13)* Cartesian Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 816212104 (CUSIP Number) Michael K. Bradshaw, Jr. Nelson Mullins Riley & Scarborough LLP 101 Constitution Avenue NW, Suite 900 Washing |
|
| April 10, 2024 |
RNAC / Cartesian Therapeutics, Inc. / Kalayoglu Murat - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Cartesian Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 816212104 (CUSIP Number) William R. Kolb Daniel S. Clevenger Foley Hoag LLP 155 Seaport Boulevard Boston, MA 02210 Tel: (617) 832-1000 |
|
| April 10, 2024 |
RNAC / Cartesian Therapeutics, Inc. / Singer Michael - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Cartesian Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 816212104 (CUSIP Number) William R. Kolb Daniel S. Clevenger Foley Hoag LLP 155 Seaport Boulevard Boston, MA 02210 Tel: (617) 832-1000 |
|
| April 9, 2024 |
® THERAPEUTICS Pioneering mRNA Cell Therapy for Autoimmunity April 2024 C A R T E S I A N T H E R A P E U T I C S Exhibit 99. |
|
| April 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 8, 2024 CARTESIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37798 26-1622110 (State or other jurisdiction of incorporation) (Commiss |
|
| April 1, 2024 |
Exhibit 10.2 Employment Agreement This Employment Agreement (this “Agreement”), dated as of March 28, 2024, is made by and between Cartesian Therapeutics, Inc., a Delaware corporation (together with any successor thereto, the “Company”), and Metin Kurtoglu (“Executive”) (collectively referred to as the “Parties” or individually referred to as a “Party”), and effective as of March 28, 2024 (the “Ef |
|
| April 1, 2024 |
Exhibit 10.1 Employment Agreement This Employment Agreement (this “Agreement”), dated as of March 26, 2024, is made by and between Cartesian Therapeutics, Inc., a Delaware corporation (together with any successor thereto, the “Company”), and Christopher Jewell (“Executive”) (collectively referred to as the “Parties” or individually referred to as a “Party”), and effective as of March 26, 2024 (the |
|
| April 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2024 CARTESIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37798 26-1622110 (State or other jurisdiction of incorporation) (Commis |
|
| March 28, 2024 |
Exhibit 99.1 Cartesian Therapeutics Announces Approval of Conversion of Series A Convertible Preferred Stock and Plans to Effect Reverse Stock Split Proposals approved at Company’s special meeting of stockholders held March 27, 2024 GAITHERSBURG, MD, March 28, 2024 (GLOBE NEWSWIRE) – Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA |
|
| March 28, 2024 |
Exhibit 3.1 CARTESIAN THERAPEUTICS, INC. Certificate of Amendment of the Certificate of Designation of Preferences, Rights and Limitations of Series A Non-Voting Convertible Preferred Stock Pursuant to Sections 228 and 242 of the General Corporation Law of the State of Delaware, the undersigned, being a duly authorized officer of Cartesian Therapeutics, Inc., a Delaware corporation (the “Company”) |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2024 CARTESIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37798 26-1622110 (State or other jurisdiction of incorporation) (Commis |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 12)* Cartesian Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 816212104 (CUSIP Number) Michael K. Bradshaw, Jr. Nelson Mullins Riley & Scarborough LLP 101 Constitution Avenue NW, Suite 900 Washing |
|
| March 28, 2024 |
Exhibit 3.2 CERTIFICATE OF AMENDMENT OF THE RESTATED CERTIFICATE OF INCORPORATION, AS AMENDED, OF CARTESIAN THERAPEUTICS, INC. (Pursuant to Section 242 of the General Corporation Law of the State of Delaware) Cartesian Therapeutics, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “Gene |
|
| March 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2024 CARTESIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37798 26-1622110 (State or other jurisdiction of incorporation) (Commiss |
|
| March 7, 2024 |
Cartesian Therapeutics, Inc. Compensation Clawback Policy Exhibit 97 Cartesian Therapeutics, Inc. Compensation Clawback Policy As of January 31, 2024 Purpose The Board of Directors (the “Board”) of Cartesian Therapeutics, Inc. (the “Corporation”) has adopted this compensation clawback policy (the “Policy”) which provides for the recoupment of incentive-based compensation in the event of an accounting restatement. This Policy is intended to comply with Se |
|
| March 7, 2024 |
Exhibit 10.11(b) [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item (601)(b)(10). Such excluded information is both (i) not material and (ii) the type that the Registrant treats as private or confidential. FIRST AMENDMENT TO LEASE AGREEMENT THIS FIRST AMENDMENT TO LEASE AGREEMENT (“this First Amendment”) is dated as of March 22, 2021 (“Effective Date”), b |
|
| March 7, 2024 |
Subsidiaries of Cartesian Therapeutics, Inc. Exhibit 21.1 Subsidiaries of Cartesian Therapeutics, Inc.: Name Jurisdiction of Organization Selecta (RUS) LLC Russia Selecta Biosciences Security Corporation Massachusetts Cartesian Bio, LLC Delaware |
|
| March 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37798 Cartesian Therapeutics, I |
|
| March 7, 2024 |
Exhibit 10.16 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item (601)(b)(10). Such excluded information is both (i) not material and (ii) the type that the Registrant treats as private or confidential. PUBLIC HEALTH SERVICE PATENT LICENSE-NON-EXCLUSIVE This Agreement is based on the model Patent License Non-exclusive Agreement adopted by the U.S. Public |
|
| March 7, 2024 |
Non-Employee Director Compensation Program Exhibit 10.6 CARTESIAN THERAPEUTICS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM Non-employee members of the board of directors (the “Board”) of Cartesian Therapeutics, Inc. (the “Company”) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this “Program”), as amended by the Board effective December 21, 2023 (the “Effective Date”). The c |
|
| March 7, 2024 |
Exhibit 10.11(c) [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item (601)(b)(10). Such excluded information is both (i) not material and (ii) the type that the Registrant treats as private or confidential. SECOND AMENDMENT TO LEASE AGREEMENT THIS SECOND AMENDMENT TO LEASE AGREEMENT (this “Second Amendment”) is dated as of May 3, 2021, by and between 704 Q |
|
| March 7, 2024 |
Exhibit 10.21 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item (601)(b)(10). Such excluded information is both (i) not material and (ii) the type that the Registrant treats as private or confidential. LICENSE AND DEVELOPMENT AGREEMENT dated January 8, 2023 by and between Selecta Biosciences, Inc. and Audentes Therapeutics, Inc. Exhibit 10.21 [***] Certa |
|
| March 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2024 CARTESIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37798 26-1622110 (State or other jurisdiction of incorporation) (Commiss |
|
| March 7, 2024 |
Exhibit 99.1 Cartesian Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update Topline data from Phase 2b study of Descartes-08, the Company’s potential first-in-class mRNA CAR-T cell therapy, in myasthenia gravis (MG) remains on track for mid-2024 On track to initiate Phase 2 study of Descartes-08 in systemic lupus erythematosus (SLE) in 1H24 as well as Phase 2 basket s |
|
| March 7, 2024 |
Exhibit 10.15(b) [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item (601)(b)(10). Such excluded information is both (i) not material and (ii) the type that the Registrant treats as private or confidential. AMENDMENT NO. 1 TO LICENSE AND DEVELOPMENT AGREEMENT This Amendment No. 1 (this “Amendment No. 1”) to the License and Development Agreement, dated as o |
|
| March 7, 2024 |
Exhibit 10.11(a) [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item (601)(b)(10). Such excluded information is both (i) not material and (ii) the type that the Registrant treats as private or confidential. LEASE AGREEMENT THIS LEASE AGREEMENT is made as of this 11th day of May, 2018, between 704 Quince Orchard Owner, LLC, a Delaware limited liability comp |
|
| March 7, 2024 |
Lease Agreement by and between 7495 RP, LLC and Cartesian Therapeutics, Inc. dated February 28, 2024 Exhibit 10.12 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item (601)(b)(10). Such excluded information is both (i) not material and (ii) the type that the Registrant treats as private or confidential. LEASE AGREEMENT THIS LEASE AGREEMENT (this “Lease”) is made and is effective this 28th day of February, 2024 (“Effective Date”) by and between 7495 RP, LL |
|
| March 7, 2024 |
Exhibit 10.17 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item (601)(b)(10). Such excluded information is both (i) not material and (ii) the type that the Registrant treats as private or confidential. NON-EXCLUSIVE PATENT LICENSE AGREEMENT This NON-EXCLUSIVE PATENT LICENSE AGREEMENT (the “Agreement”) is made and effective September 8, 2023 (the “Effecti |
|
| March 7, 2024 |
Exhibit 4.14 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED As of December 31, 2023, Cartesian Therapeutics, Inc. (the “Company,” “we,” “us” and “our”) had two classes of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock, par value $0.0001 per share (“common st |
|
| March 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2024 CARTESIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37798 26-1622110 (State or other jurisdiction of incorporation) (Com |
|
| March 5, 2024 |
Exhibit 99.1 Cartesian Therapeutics Establishes New Corporate Headquarters and State-of-the-Art mRNA Cell Therapy cGMP Manufacturing Facility in Frederick, Maryland – New facility expected to support expanded cGMP manufacturing of clinical and commercial supply of Company’s pipeline of mRNA cell therapies for the treatment of autoimmune diseases – GAITHERSBURG, MD, March 5, 2024 (GLOBE NEWSWIRE) – |
|
| February 14, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Con |
|
| February 14, 2024 |
SELB / Selecta Biosciences Inc / MANGROVE PARTNERS Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use |
|
| February 9, 2024 |
SELB / Selecta Biosciences Inc / Artal International S.C.A. - SC 13G/A Passive Investment SC 13G/A 1 d766103dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* (Amendment No. 1) Cartesian Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 816212104 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statemen |
|
| January 31, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Conf |
|
| January 23, 2024 |
Cartesian Therapeutics, Inc. Balance Sheets (Amounts in thousands, except share data) Exhibit 99.1 Independent Auditor’s Report Board of Directors Cartesian Therapeutics, Inc. 704 Quince Orchard Road Gaithersburg, MD 20878 Opinion We have audited the financial statements of Cartesian Therapeutics, Inc. (the Company), which comprise the balance sheets as of December 31, 2022 and 2021, and the related statements of operations and comprehensive loss, preferred stock and stockholders’ |
|
| January 23, 2024 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Exhibit 99.3 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION On November 13, 2023, Selecta Biosciences, Inc., a Delaware corporation (“Selecta”), acquired Cartesian Therapeutics, Inc., a Delaware corporation (“Old Cartesian”), in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023 (the “Merger Agreement”), by and among Selecta, Sakura Merger Sub I, In |
|
| January 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2023 CARTESIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37798 26-1622110 (State or other jurisdiction of |
|
| January 23, 2024 |
Cartesian Therapeutics, Inc. Balance Sheets (Amounts in thousands, except share data) Exhibit 99.2 Cartesian Therapeutics, Inc. Balance Sheets (Amounts in thousands, except share data) (Unaudited) September 30, 2023 December 31, 2022 Assets Current assets: Cash and cash equivalents $ 6,875 $ 12,001 Accounts receivable 994 994 Payroll tax credit receivable 248 351 Prepaid expenses and other current assets 51 59 Total current assets $ 8,168 $ 13,405 Non-current assets: Property and e |
|
| January 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 17, 2024 CARTESIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37798 26-1622110 (State or other jurisdiction of incorporation) (Comm |
|
| January 12, 2024 |
Cartesian Therapeutics, Inc. 2016 Stock Incentive Plan, and forms of award agreements thereunder Exhibit 99.1 CARTESIAN THERAPEUTICS, INC. 2016 STOCK INCENTIVE PLAN 1. Purpose The purpose of this 2016 Stock Incentive Plan (the "Plan") of Cartesian Therapeutics, Inc., a Delaware corporation (the "Company"), is to advance the interests of the Company's stockholders by enhancing the Company's ability to attract, retain and motivate persons who make (or are expected to make) important contributio |
|
| January 12, 2024 |
Exhibit 99.2 CARTESIAN THERAPEUTICS, INC. AMENDED AND RESTATED 2018 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN ARTICLE I. PURPOSE The Plan’s purpose is to enhance the Company’s ability to attract, retain and motivate persons who are expected to make important contributions to the Company by providing these individuals with equity ownership opportunities. Capitalized terms used in the Plan are defi |
|
| January 12, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Cartesian Therapeutics, Inc. |
|
| January 12, 2024 |
As filed with the Securities and Exchange Commission on January 12, 2024 As filed with the Securities and Exchange Commission on January 12, 2024 Registration No. |
|
| January 8, 2024 |
Exhibit 99.3 Cartesian Therapeutics Highlights Progress and 2024 Strategic Priorities Across Innovative Pipeline of mRNA Cell Therapies for Autoimmunity Topline data from Phase 2b study of Descartes-08, the Company’s potential first-in-class mRNA CAR-T cell therapy in myasthenia gravis (MG) remains on track for mid-2024 Positive 12-month follow-up data from Phase 2a study in MG reported today; dur |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 CARTESIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37798 26-1622110 (State or other jurisdiction of incorporation) (Commi |
|
| January 8, 2024 |
Exhibit 99.1 ® THERAPEUTICS Pioneering mRNA Cell Therapy for Autoimmunity January 2024 C A R T ES I AN T H E R APEUT I CS Forward-Looking Statements Disclosures For the purposes of this notice, the “presentation” that follows shall mean and include the slides that follow, the oral presentation of the slides by members of management of Cartesian Therapeutics, Inc. (the “Company”) or any person on t |
|
| January 8, 2024 |
Exhibit 99.2 Cartesian Therapeutics Announces Positive Long-Term Follow-Up Data from Phase 2a Study of Lead mRNA Cell Therapy Candidate Descartes-08 in Patients with Myasthenia Gravis Durable depletion of autoantibodies and clinically meaningful improvements in myasthenia gravis (MG) severity scores observed after one-year follow-up period without need for lymphodepleting chemotherapy Descartes-08 |
|
| December 8, 2023 |
8-A12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 CARTESIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 26-1622110 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identi |
|
| December 8, 2023 |
EX-4.1 Exhibit 4.1 Execution Version CONTINGENT VALUE RIGHTS AGREEMENT by and between CARTESIAN THERAPEUTICS, INC. and EQUINITI TRUST COMPANY, LLC, as Trustee Dated as of December 6, 2023 TABLE OF CONTENTS Article I DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 2 Section 1.1 Definitions 2 Section 1.2 Compliance and Opinions 10 Section 1.3 Form of Documents Delivered to Trustee 10 Section |
|
| December 1, 2023 |
As filed with the Securities and Exchange Commission on December 1, 2023 S-3/A As filed with the Securities and Exchange Commission on December 1, 2023 Registration No. |
|
| December 1, 2023 |
December 1, 2023 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Tamika Sheppard Re: Cartesian Therapeutics, Inc. Registration Statement Filed on Form S-3, as amended on December 1, 2023 (the “Registration Statement”) File No. 333-275171 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as |
|
| November 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 21, 2023 CARTESIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37798 26-1622110 (State or other jurisdiction of incorporation) (Com |
|
| November 22, 2023 |
EX-99.4 5 d461930dex994.htm EX-99.4 Exhibit 99.4 Exhibit 4 CONFIRMING STATEMENT This Statement confirms that the undersigned has authorized and designated Michael Singer to execute and file on the undersigned’s behalf all Forms 3, 4 and 5 and Schedules 13D and 13G (including any amendments thereto) that the undersigned may be required to file with the U.S. Securities and Exchange Commission as a r |
|
| November 22, 2023 |
EX-99.3 4 d503994dex993.htm EX-99.3 Exhibit 3 CONFIRMING STATEMENT This Statement confirms that the undersigned has authorized and designated Murat Kalayoglu to execute and file on the undersigned’s behalf all Forms 3, 4 and 5 and Schedules 13D and 13G (including any amendments thereto) that the undersigned may be required to file with the U.S. Securities and Exchange Commission as a result of the |
|
| November 22, 2023 |
EX-99.5 6 d461930dex995.htm EX-99.5 Exhibit 99.5 Exhibit 5 CONFIRMING STATEMENT This Statement confirms that the undersigned has authorized and designated Michael Singer to execute and file on the undersigned’s behalf all Forms 3, 4 and 5 and Schedules 13D and 13G (including any amendments thereto) that the undersigned may be required to file with the U.S. Securities and Exchange Commission as a r |
|
| November 22, 2023 |
EX-99.6 7 d461930dex996.htm EX-99.6 Exhibit 99.6 Exhibit 6 CONFIRMING STATEMENT This Statement confirms that the undersigned has authorized and designated Michael Singer to execute and file on the undersigned’s behalf all Forms 3, 4 and 5 and Schedules 13D and 13G (including any amendments thereto) that the undersigned may be required to file with the U.S. Securities and Exchange Commission as a r |
|
| November 22, 2023 |
EX-99.3 4 d461930dex993.htm EX-99.3 Exhibit 99.3 Exhibit 3 CONFIRMING STATEMENT This Statement confirms that the undersigned has authorized and designated Michael Singer to execute and file on the undersigned’s behalf all Forms 3, 4 and 5 and Schedules 13D and 13G (including any amendments thereto) that the undersigned may be required to file with the U.S. Securities and Exchange Commission as a r |
|
| November 22, 2023 |
EX-99.4 5 d503994dex994.htm EX-99.4 Exhibit 4 CONFIRMING STATEMENT This Statement confirms that the undersigned has authorized and designated Murat Kalayoglu to execute and file on the undersigned’s behalf all Forms 3, 4 and 5 and Schedules 13D and 13G (including any amendments thereto) that the undersigned may be required to file with the U.S. Securities and Exchange Commission as a result of the |
|
| November 22, 2023 |
EX-99.1 2 d503994dex991.htm EX-99.1 Exhibit 1 JOINT FILING AGREEMENT Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree, as of November 22, 2023, that only one statement containing the information required by Schedule 13D, and each amendment thereto, need be filed with respect to the ownership of each of the undersigned of shares of com |
|
| November 22, 2023 |
EX-99.2 3 d461930dex992.htm EX-99.2 Exhibit 99.2 Exhibit 2 CONFIRMING STATEMENT This Statement confirms that the undersigned has authorized and designated Michael Singer to execute and file on the undersigned’s behalf all Forms 3, 4 and 5 and Schedules 13D and 13G (including any amendments thereto) that the undersigned may be required to file with the U.S. Securities and Exchange Commission as a r |
|
| November 22, 2023 |
EX-99.1 2 d461930dex991.htm EX-99.1 Exhibit 99.1 Exhibit 1 JOINT FILING AGREEMENT Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree, as of November 22, 2023, that only one statement containing the information required by Schedule 13D, and each amendment thereto, need be filed with respect to the ownership of each of the undersigned of |
|
| November 22, 2023 |
EX-99.2 3 d503994dex992.htm EX-99.2 Exhibit 2 CONFIRMING STATEMENT This Statement confirms that the undersigned has authorized and designated Murat Kalayoglu to execute and file on the undersigned’s behalf all Forms 3, 4 and 5 and Schedules 13D and 13G (including any amendments thereto) that the undersigned may be required to file with the U.S. Securities and Exchange Commission as a result of the |
|
| November 22, 2023 |
SELB / Selecta Biosciences Inc / Kalayoglu Murat - SC 13D Activist Investment SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Cartesian Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 816212104 (CUSIP Number) William R. Kolb Daniel S. Clevenger Foley Hoag LLP 155 Seaport Boulevard Boston, MA 02210 Tel: (617) 832-1000 Fax: |
|
| November 22, 2023 |
SELB / Selecta Biosciences Inc / Singer Michael - SC 13D Activist Investment SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Cartesian Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 816212104 (CUSIP Number) William R. Kolb Daniel S. Clevenger Foley Hoag LLP 155 Seaport Boulevard Boston, MA 02210 Tel: (617) 832-1000 Fax: |
|
| November 17, 2023 |
SC 13D/A 1 ea188568-13da11springcart.htm AMENDMENT NO. 11 TO SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 11)* Cartesian Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 816212104 (CUSIP Number) Michael K. Bradshaw, Jr. Nelson Mul |
|
| November 13, 2023 |
Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER by and among SELECTA BIOSCIENCES, INC., a Delaware corporation SAKURA MERGER SUB I, INC., a Delaware corporation SAKURA MERGER SUB II, LLC, a Delaware limited liability company and CARTESIAN THERAPEUTICS, INC., a Delaware corporation Dated as of November 13, 2023 Execution Version TABLE OF CONTENTS Page ARTICLE I. DESCRIPTION OF TRANSACTIO |
|
| November 13, 2023 |
Exhibit 99.1 Disclosures For the purposes of this notice, the “presentation” that follows shall mean and include the slides that follow, the oral presentation of the slides by members of management of Selecta Biosciences, Inc. (“Selecta”) and Cartesian Therapeutics, Inc. (“Cartesian”) or any person on their behalf, any question-and-answer session that follows such oral presentation, hard copies of |
|
| November 13, 2023 |
Amended and Restated By-laws of Cartesian Therapeutics, Inc. Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF CARTESIAN THERAPEUTICS, INC. (a Delaware corporation) TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROCEDURES FOR BUSINESS BROUGHT BEFORE A MEETING 2 2.5 ADVANCE NOTICE PROCEDUR |
|
| November 13, 2023 |
Form of Retention Bonus Letter Exhibit 10.3 November [●], 2023 [Name] Delivered Electronically: [email] Re: Retention Bonus Dear [Name], Reference is made to the letter you received from Selecta Biosciences, Inc. (“Selecta” or the “Company”) on or about September 8, 2023, informing you of a cash retention bonus in the amount of [$DOLLAR AMOUNT] (the “Retention Bonus”) to be paid to you subject to your continued employment with |
|
| November 13, 2023 |
Exhibit 3.3 CERTIFICATE OF AMENDMENT OF RESTATED CERTIFICATE OF INCORPORATION OF SELECTA BIOSCIENCES, INC. Selecta Biosciences, Inc. (the “Corporation”), a corporation duly organized and existing under and by virtue of the Delaware General Corporation Law, does hereby certify as follows: 1. The Corporation’s Certificate of Incorporation was originally filed on December 10, 2007 with the Secretary |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2023 SELECTA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37798 26-1622110 (State or other jurisdiction of incorporation) (Commis |
|
| November 13, 2023 |
Exhibit 10.1 Execution Version SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of November 13, 2023, by and among SELECTA BIOSCIENCES, INC., a Delaware corporation (the “Company”), and each purchaser identified on Annex A hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). RECITALS A. The Company and |
|
| November 13, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-3779 |
|
| November 13, 2023 |
Exhibit 10.2 Execution Version REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is dated as of November 13, 2023, by and among Selecta Biosciences, Inc., a Delaware corporation (the “Company”), and the several parties signatory hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). This Agreement is made in connecti |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2023 SELECTA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37798 26-1622110 (State or other jurisdiction of incorporation) (Commis |
|
| November 13, 2023 |
Exhibit 3.4 SELECTA BIOSCIENCES, INC. FORM OF CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES A NON-VOTING CONVERTIBLE PREFERRED STOCK Pursuant to Section 151 of the General Corporation Law of the State of Delaware THE UNDERSIGNED DOES HEREBY CERTIFY, on behalf of Selecta Biosciences, Inc., a Delaware corporation (the “Corporation”), that the following resolution was du |
|
| November 13, 2023 |
Exhibit 99.2 Selecta Biosciences Announces Merger with Cartesian Therapeutics – Merger creates a fully integrated, publicly traded company pioneering RNA cell therapy for the treatment of autoimmune disease – – Cartesian’s wholly owned pipeline includes a Phase 2 lead asset, Descartes-08, for which deep and durable responses have been observed in patients with myasthenia gravis (MG) – – Multiple n |
|
| October 31, 2023 |
Exhibit 99.1 Selecta Announces Transition of Manufacturing and Clinical Operations of ImmTOR for SEL-212 to Commercialization Partner Sobi WATERTOWN, Mass., October 31, 2023 (GLOBE NEWSWIRE) – Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies for autoimmune diseases and gene therapies, today annou |
|
| October 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2023 SELECTA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37798 26-1622110 (State or other jurisdiction of incorporation) (Commiss |
|
| October 30, 2023 |
October 30, 2023 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Tamika Sheppard Re: Selecta Biosciences, Inc. Registration Statement Filed on Form S-3 (the “Registration Statement”) File No. 333-275171 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Selecta Biosciences, Inc. |
|
| October 25, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Selecta Biosciences, Inc. |
|
| October 25, 2023 |
Exhibit 4.2 SELECTA BIOSCIENCES, INC. INDENTURE Dated as of , 20 [] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Other Definitions 4 Section 1.3. Incorporation by Reference of Trust Indenture Act 4 Section 1.4. Rules of Construction 5 ARTICLE II. THE SECURITIES 5 Section 2.1. Issuable in Series 5 Section 2.2. Establi |
|
| October 25, 2023 |
As filed with the Securities and Exchange Commission on October 25, 2023 Table of Contents As filed with the Securities and Exchange Commission on October 25, 2023 Registration No. |
|
| September 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 25, 2023 SELECTA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37798 26-1622110 (State or other jurisdiction of incorporation) (Commissi |
|
| September 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 10)* Selecta Biosciences, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 816212104 (CUSIP Number) Michael K. Bradshaw, Jr. Nelson Mullins Riley & Scarborough LLP 101 Constitution Avenue NW, Suite 900 Washington |
|
| September 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 11, 2023 SELECTA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37798 26-1622110 (State or other jurisdiction of incorporation) (Commi |
|
| August 17, 2023 |
Exhibit 99.1 Selecta Biosciences Reports Second Quarter 2023 Financial Results and Updates on Strategic Initiative Designed to Maximize Stockholder Value Associated with SEL-212 Economics – Company to continue focusing on advancement of SEL-212, a potential treatment for chronic refractory gout; Biologics License Application (BLA) filing on track for 1H 2024 – – Company to suspend further investme |
|
| August 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 17, 2023 SELECTA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37798 26-1622110 (State or other jurisdiction of incorporation) (Commissi |
|
| August 17, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37798 Sel |
|
| August 17, 2023 |
Exhibit 107.1 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) Selecta Biosciences, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1 - Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount to be Registered (1) Proposed Maximum Offering Price Per Share Proposed Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Com |
|
| August 17, 2023 |
As filed with the Securities and Exchange Commission on August 17, 2023 S-8 As filed with the Securities and Exchange Commission on August 17, 2023 Registration No. |
|
| August 14, 2023 |
NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC File Number: 001-37798 NOTIFICATION OF LATE FILING (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: June 30, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on |
|
| June 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2023 SELECTA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37798 26-1622110 (State or other jurisdiction of incorporation) (Commission |
|
| June 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| June 12, 2023 |
SELB / Selecta Biosciences Inc / Artal International S.C.A. - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* (Amendment No. ) Selecta Biosciences, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 816212104 (CUSIP Number) June 1, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| June 12, 2023 |
EX-99.1 EXHIBIT 1 JOINT FILING AGREEMENT The undersigned agree that the statement on Schedule 13G with respect to the Common Stock, $0.0001 par value per share, of Selecta Biosciences, Inc. is, and any amendments thereto signed by each of the undersigned shall be, filed on behalf of each of them pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37798 Selecta Biosciences, |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant þ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) þ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Pursuant to § 240. |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Pursuant to § 240. |
|
| April 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2023 SELECTA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37798 26-1622110 (State or other jurisdiction of incorporation) (Commissio |
|
| April 4, 2023 |
Exhibit 10.1 FOURTH AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS FOURTH AMENDMENT to Loan and Security Agreement (this “Amendment”) is entered into as of March 31, 2023, by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, Virginia 22314 (“Oxford”), as collateral agent (in such capacity, “Collateral Agent”), |
|
| March 21, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2023 SELECTA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37798 26-1622110 (State or other jurisdiction of incorporation) (Commissio |
|
| March 21, 2023 |
EX-99.1 Exhibit 99.1 Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout Meets Primary Endpoint —Response rate of 56% in patients treated monthly with high dose SEL-212 in DISSOLVE I and 47% in DISSOLVE II —In patients 50 years and older, response rate with high dose SEL-212 was 65% in DISSOLVE I and 48% in DISSOLVE II —75% of subjects in the DISSOLVE I extension phase on active treatme |
|
| March 21, 2023 |
EX-99.2 3 d485004dex992.htm EX-99.2 Exhibit 99.2 SELB DISSOLVE I & II Phase 3 Clinical Trials: Topline Data For release on March 21, 2023 Forward-looking statements Any statements in this presentation about the future expectations, plans and prospects of Selecta Biosciences, Inc. (the “Company”), including without limitation, statements regarding the Company’s cash runway, the unique proprietary t |
|
| March 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37798 Selecta Biosciences, Inc. |
|
| March 2, 2023 |
, 2022, by and between the Registrant and Kevin Tan Exhibit 10.16 Separation Agreement and Release This Separation Agreement and Release (“Agreement”) is made by and between Kevin Tan (“Executive”) and Selecta Biosciences, Inc. (the “Company”) (collectively referred to as the “Parties” or individually referred to as a “Party”). Capitalized terms used but not defined in this Agreement shall have the meanings set forth in the Employment Agreement (as |
|
| March 2, 2023 |
Employment Agreement, dated as of November 9, 2022, by and between the Registrant and Blaine Davis Exhibit 10.15 Employment Agreement This Employment Agreement (this “Agreement”), dated as of November 9, 2022, is made by and between Selecta Biosciences, Inc., a Delaware corporation (together with any successor thereto, the “Company”), and Blaine Davis (“Executive”) (collectively referred to as the “Parties” or individually referred to as a “Party”), and effective as of Nov. 28, 2022 (the “Effec |
|
| March 2, 2023 |
Exhibit 4.8(b) FORM OF COMMON STOCK WARRANT THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUED UPON ITS EXERCISE ARE SUBJECT TO THE RESTRICTIONS ON TRANSFER SET FORTH IN SECTION 5 OF THIS WARRANT Warrant No. CS-[●] Number of Shares: [●] (subject to adjustment) Date of Issuance: December 23, 2019 Original Issue Date (as defined in subsection 2(a)): December 23, 2019 Selecta Biosciences, Inc. Common |
|
| March 2, 2023 |
Non-Employee Director Compensation Program Exhibit 10.5 SELECTA BIOSCIENCES, INC. NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM Non-employee members of the board of directors (the “Board”) of Selecta Biosciences, Inc. (the “Company”) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this “Program”), as amended by the Board effective March 16, 2021 (the “Effective Date”). The cash and e |
|
| March 2, 2023 |
Exhibit 4.11 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED As of December 31, 2022, Selecta Biosciences, Inc. (the “Company,” “we,” “us” and “our”) had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock, par value $0.0001 per share (“common stock”) |
|
| February 14, 2023 |
SELB / Selecta Biosciences Inc / MANGROVE PARTNERS Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| January 9, 2023 |
January 2023 Selecta Biosciences Corporate Presentation SELB 2Selecta Biosciences Investor Presentation – January 2023 Any statements in this presentation about the future expectations, plans and prospects of Selecta Biosciences, Inc. |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2023 SELECTA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37798 26-1622110 (State or other jurisdiction of incorporation) (Commissi |
|
| January 9, 2023 |
Exhibit 99.2 Selecta Biosciences Provides Business Update and Outlook for 2023 -Expected topline data for Phase 3 DISSOLVE I & II programs of SEL-212 in chronic refractory gout in Q1 2023- -To receive $10 million upfront for the execution of a license agreement- for Xork the Company’s next-generation immunoglobulin G (IgG) protease candidate to be developed with Astellas Gene Therapies’ AT845, an |
|
| January 9, 2023 |
Exhibit 99.1 Press Release Selecta Biosciences and Astellas Announce Exclusive Licensing and Development Agreement for Xork IgG Protease Next-generation IgG protease candidate Xork to be licensed for development with AT845, an investigational Astellas Gene Therapies’ product, for the treatment of Pompe Disease Selecta to receive a $10M upfront payment and eligible to receive up to $340M for certai |
|
| December 14, 2022 |
Exhibit 99.1 Selecta Biosciences Announces Next Generation IgA Protease Clinical Candidate Selection for IgA Nephropathy Program –IgA protease candidate in combination with ImmTOR further enhances pipeline – – Novel mechanism of action of IgA protease has the potential to address the underlying kidney pathophysiology of IgA nephropathy – WATERTOWN, Mass. December 14, 2022 - Selecta Biosciences, In |
|
| December 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2022 SELECTA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37798 26-1622110 (State or other jurisdiction of incorporation) (Commis |
|
| November 28, 2022 |
Selecta Biosciences Announces Appointment of Blaine Davis as Chief Financial Officer EX-99.1 Exhibit 99.1 Selecta Biosciences Announces Appointment of Blaine Davis as Chief Financial Officer WATERTOWN, Mass. November 28, 2022 — Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies for autoimmune diseases, unlock the potential of gene therapies and amplify the efficacy of biologic ther |
|
| November 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 22, 2022 SELECTA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37798 26-1622110 (State or other jurisdiction of incorporation) (Commis |
|
| November 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 18, 2022 SELECTA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37798 26-1622110 (State or other jurisdiction of incorporation) (Commis |
|
| November 18, 2022 |
selbcorporatexpresentat November 2022 Selecta Biosciences Corporate Presentation SELB 2Selecta Biosciences Investor Presentation – November 2022 Any statements in this presentation about the future expectations, plans and prospects of Selecta Biosciences, Inc. |
|
| November 3, 2022 |
Exhibit 10.1 FIRST AMENDMENT TO LEASE THIS FIRST AMENDMENT TO LEASE (this ?Amendment?) is entered into as of this 1st day of September, 2022, by and between BRE-BMR GROVE LLC, a Delaware limited liability company (?Landlord?), and Selecta Biosciences, Inc., a Delaware corporation (?Tenant?). RECITALS A.WHEREAS, Landlord and Tenant are parties to that certain Lease dated as of July 23, 2019 (as the |
|
| November 3, 2022 |
Exhibit 10.2 THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS THIRD AMENDMENT to Loan and Security Agreement (this ?Amendment?) is entered into as of September 20, 2022, by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, Virginia 22314 (?Oxford?), as collateral agent (in such capacity, ?Collateral Agent? |
|
| November 3, 2022 |
Exhibit 99.1 Selecta Biosciences Reports Third Quarter 2022 Financial Results and Provides Business Update — DISSOLVE I & II studies of SEL-212 in Chronic Refractory Gout remain on track for joint topline data readout in Q1 2023 — — SEL-302, Selecta’s wholly owned gene therapy in combination with ImmTOR for the treatment of Methylmalonic Acidemia (MMA), remains on track to begin a Phase 1 trial in |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37798 Selecta Bioscien |
|
| November 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2022 SELECTA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37798 26-1622110 (State or other jurisdiction of incorporation) (Commiss |
|
| August 22, 2022 |
Amended and Restated By-laws of Selecta Biosciences, Inc. Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF SELECTA BIOSCIENCES, INC. (a Delaware corporation) TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROCEDURES FOR BUSINESS BROUGHT BEFORE A MEETING 1 2.5 ADVANCE NOTICE PROCEDURES |
|
| August 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2022 SELECTA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37798 26-1622110 (State or other jurisdiction of incorporation) (Commissi |
|
| August 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37798 Selecta Biosciences, |
|
| August 4, 2022 |
Exhibit 99.1 Selecta Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update ? Completed enrollment of DISSOLVE II, triggering a $10 million milestone payment obligation from Swedish Orphan Biovitrum AB (publ.) (Sobi); DISSOLVE I & II studies remain on track for joint topline data readout in Q1 2023 ? ? Sarepta extends Option and License agreement in exchange for a $ |
|
| August 4, 2022 |
August 2022 Selecta Biosciences Corporate Presentation SELB 2Selecta Biosciences Investor Presentation ? August 2022 Any statements in this presentation about the future expectations, plans and prospects of Selecta Biosciences, Inc. |
|
| August 4, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2022 SELECTA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37798 26-1622110 (State or other jurisdiction of incorporation) (Commissio |
|
| August 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2022 SELECTA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37798 26-1622110 (State or other jurisdiction of incorporation) (Commissio |
|
| July 27, 2022 |
SELB / Selecta Biosciences Inc / MANGROVE PARTNERS Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| June 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2022 SELECTA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37798 26-1622110 (State or other jurisdiction of incorporation) (Commission |
|
| June 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2022 SELECTA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37798 26-1622110 (State or other jurisdiction of incorporation) (Commission |
|
| June 21, 2022 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT OF THE RESTATED CERTIFICATE OF INCORPORATION OF SELECTA BIOSCIENCES, INC. (Pursuant to Section 242 of the General Corporation Law of the State of Delaware) Selecta Biosciences, Inc. (the ?Corporation?), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the ?General Corporation Law |
|
| June 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2022 SELECTA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37798 26-1622110 (State or other jurisdiction of incorporation) (Commission |
|
| June 17, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2022 SELECTA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37798 26-1622110 (State or other jurisdiction of incorporation) (Commission |
|
| June 13, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2022 SELECTA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37798 26-1622110 (State or other jurisdiction of incorporation) (Commission |
|
| June 13, 2022 |
Selecta Biosciences Announces Partnership Advancements and Clinical Trial Updates Exhibit 99.1 Selecta Biosciences Announces Partnership Advancements and Clinical Trial Updates ?Sarepta extends Research License and Option Agreement for ImmTOR? in Duchenne Muscular Dystrophy and certain Limb-Girdle Muscular Dystrophies- ?Selecta to receive a $2 million payment from Sarepta extending their option periods under the agreement to Q1 2023- ?Enrollment in DISSOLVE II, the Phase 3 stud |
|
| June 3, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2022 SELECTA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37798 26-1622110 (State or other jurisdiction of incorporation) (Commission |
|
| May 24, 2022 |
SELB / Selecta Biosciences Inc / MANGROVE PARTNERS Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
